Pacira Biosciences Inc Stock Price, News & Analysis

PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:30 AM ET. The event can be accessed via the company's website, with a replay available for two weeks after the presentation. Pacira is a leader in non-opioid pain management, known for its long-acting local analgesic EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance and enhance patient care through innovative solutions, including the iovera°® cryoanalgesia device acquired in 2019.

Pacira BioSciences has received a Notice of Allowance from the USPTO for a patent regarding its EXPAREL manufacturing process, extending protection until January 22, 2041. This patent is a key component of the company's strategy to maintain market exclusivity for EXPAREL, a non-opioid pain management solution. The company has invested over $100 million in developing a more efficient manufacturing method. Additionally, Pacira is awaiting FDA approval for its new manufacturing process, with a PDUFA date set for August 6, 2021.

Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 10:20 AM ET. The virtual event will feature live audio accessible via the company’s website. A replay will be available for two weeks post-event.

Pacira is a leader in non-opioid pain management solutions, known for its long-acting local analgesic, EXPAREL®, which was launched in April 2012. In 2019, the company expanded its portfolio by acquiring the iovera°® system, enhancing its commitment to innovative pain management.

Pacira BioSciences reported preliminary unaudited net product sales for April 2021, achieving $43.1 million for EXPAREL and $1.5 million for iovera°. April's average daily sales of EXPAREL reached 449% of April 2020, driven by a recovery in elective surgeries as COVID-19 restrictions eased. CEO Dave Stack highlighted the growing demand for non-opioid pain management solutions. However, the company continues to face challenges due to the pandemic, which impacted elective surgical procedures. Monthly sales updates will be provided until clearer trends emerge.

Pacira BioSciences (PCRX) reported robust Q1 2021 results with total revenues of $119 million, up from $105.7 million in Q1 2020. GAAP net income reached $10.4 million or $0.24 per share, compared to $8.2 million or $0.19 last year. EXPAREL sales surged to $114.7 million, a notable increase from $101.3 million. The company experienced rising operational expenses at $99.6 million. Pacira continues to navigate COVID-19's impact on elective surgeries, with a strong outlook as recovery progresses.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its first quarter financial results on May 4, 2021, before U.S. markets open. The company will host a live conference call at 8:30 a.m. ET to discuss these results. Interested parties can participate by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) with passcode 8238109. The call will be available for replay for one week. Pacira is known for its commitment to non-opioid pain management, notably through its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia device.

Pacira BioSciences, Inc. (Nasdaq: PCRX) has announced a $3 million investment in Spine BioPharma via a convertible note, aimed at advancing Spine's lead candidate, Remedisc™, a novel therapeutic for degenerative disc disease. An additional $7 million investment is contingent upon achieving specific milestones. This initiative aligns with Pacira's commitment to non-opioid pain management, targeting the underlying causes of degenerative disc disease to improve patient outcomes. Remedisc is expected to enter Phase 2/3 trials later this year.

Pacira BioSciences, Inc. (Nasdaq: PCRX) has filed a lawsuit against the American Society of Anesthesiologists (ASA) over misleading studies published in their journal regarding EXPAREL (bupivacaine liposome injectable suspension), which claim it is not effective for pain management. The lawsuit seeks damages and retraction of the articles, accusing the ASA of publishing scientifically unsound conclusions while failing to disclose financial conflicts of interest. Pacira aims to remove these misleading materials to prevent confusion among healthcare stakeholders.

Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for Q1 2021: $114.7 million for EXPAREL and $3.3 million for iovera°. March sales reached $44.3 million for EXPAREL, marking a significant year-on-year increase. The company highlights U.S. regulatory approval for EXPAREL in pediatrics and a trend towards outpatient care, despite ongoing COVID-19 impacts on elective surgeries. Pacira plans to provide monthly sales updates to maintain transparency.